C Michael Gibson Discussing The Results of The Phase III OCEANIC-STROKE Trial with Mike Sharma
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%.
The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.
There was no increase in mild or severe bleeding or intracranial bleeding
63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy
Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin
All benefit with no increase in bleeding risk
View slides here.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
May 11, 2026, 01:38Heghine Khachatryan: The Emerging Era of Immunothrombosis and Precision Vascular Medicine
-
May 10, 2026, 18:07Recurrent DVT and PE in Young Adults May Indicate an Underlying Cause – The Lancet Group
-
May 10, 2026, 18:06Noemi Zampatti: Pediatric Celiac Crisis Complicated by Refeeding Syndrome and Proposed Diagnostic Criteria
-
May 10, 2026, 18:05Giovanni Solimeno: When the Common Femoral Artery Wall is Diseased, Closure is Not a Step
-
May 10, 2026, 18:04Maitri Vaishnav: The Bombay Blood Group and the Critical Role of the H Antigen
-
May 10, 2026, 18:03Nicolas Hubacz: Mesenchymal Stem Cells Are Some of the Most Fascinating Cells in Regenerative Medicine
-
May 10, 2026, 16:20Joshua Ngimbwa: How Sex and Socioeconomic Factors Influence Stroke Outcomes in Tanzania
-
May 10, 2026, 16:18Gustavo Monnerat: How Thousands of Fake References Slipped Into Biomedical Literature
-
May 10, 2026, 16:13Dalius Jatužis: Our AI-Driven Automated Stroke Registry Data Extraction Gets Best Poster Award at ESOC 2026